Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2018-11-07 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'PanGen' (주)팬젠, covering the period from January 1, 2018, to September 30, 2018. It contains detailed company information, management history, capital changes, and business descriptions, which are characteristic of a comprehensive interim financial report. It is not a short announcement or a certification letter, but the full report itself. 9M 2018
2018-11-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of major shareholders (the '5% rule' reporting). This falls under the category of Major Shareholding Notification.
2018-10-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, vesting period, and valuation methodology. Since this document pertains to the issuance of stock options (a form of capital/equity-related incentive) and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new share issuance), it is best classified as a general regulatory filing under the RNS category.
2018-10-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.